Pre-made Glembatumumab Vedotin benchmark antibody (Whole mAb ADC, anti-GPNMB therapeutic antibody, Anti-HGFIN/NMB/PLCA3 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Glembatumumab Vedotin benchmark antibody (Whole mAb ADC, anti-GPNMB therapeutic antibody, Anti-HGFIN/NMB/PLCA3 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Glembatumumab vedotin (also known as CDX-11 and CR11-vcMMAE) is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-856-1mg	1mg	4635
GMP-Bios-INN-856-10mg	10mg	Inquiry
GMP-Bios-INN-856-100mg	100mg	Inquiry
GMP-Bios-INN-856-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Glembatumumab Vedotin Biosimilar, Whole Mab Adc, Anti-Gpnmb Antibody: Anti-HGFIN/NMB/PLCA3 therapeutic antibody Drug Conjugate
INN Name	Glembatumumab Vedotin
Target	GPNMB
Format	Whole mAb ADC
Derivation	human
Species Reactivity	human
CH1 Isotype	IgG2 - kappa
VD LC	IgG2 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Celldex Therapeutics, Inc. (Needham MA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	Abgenix's XenoMouse®